A clinical study was made on 117 cases of benign prostatic hyperplasia admitted to the Department of Urology, Chungnam University Hospital during the period from January 1974 to August 1982. The results were summarized as follows: 1. Common symptoms were dysuria (82.1%) and urinary retention (41.0%). 2. Gross or microscopic hematuria was noticed in 48 cases (41.0%). 3. The degree of prostatic enlargement by rectal palpation was not related to the severity of symptoms. 4. Pulmonary disease (19.5%) and cardiac disease (12.8%) were frequently associated with B.P.H. 5. Treatment consisted of suprapubic of retropubic prostatectomy in 94 cases, TUR in 7 cases and cystostomy in 10 cases. 6. Postoperative complications were urinary incontinence (34%), wound problem (9.7%), delayed bleeding (8.7%), and urinary tract infection (4.8%). 7. Mean weight of removed prostatic tissue was 31.3gm.
Chungcheongnam-do ; Cystostomy ; Digital Rectal Examination ; Dysuria ; Heart Diseases ; Hematuria ; Hemorrhage ; Lung Diseases ; Postoperative Complications ; Prostatectomy ; Prostatic Hyperplasia* ; Urinary Incontinence ; Urinary Retention ; Urinary Tract Infections ; Urology ; Wounds and Injuries

PURPOSE: We investigated the effectiveness and safety of DA-3030 for prophylatic use in patients receiving chemotherapy for malignant disease. MATERIALS AND METHODS: Seventy cancer patients were randomized to receive chemotherapy alone (36 patients) or with DA-3030 administered (34 patients) after stratified block randomization according to chemotherapeutic regimen. DA-3030 was subcutaneously administered at the dose of 100 pg/m/day for 10 days from 24 hours after the completion of chemotherapy. RESULTS: Of the 70 enrolled patients, 62 patients were evaluable. The neutropenia (absolute neutrophil count [ANC] <1,000/mm) occurred in 9 of 32 (28.1%) of the DA-3030 group and 21 of 30 (90.0%) of the control group, giving relative risk for control group of 0.154 (95% confidence interval [CI], 0.05 to 0.45; p-0.0001). Severe neutropenia (ANC 500/mm') occurred in 4 of 32 (12.5%) of the DA-3030 group and in 20 of 30 (66.7%) of the control group (relative risk for control group of 0.316 [95% CI, 0,18 to 0.55]; p=0.0001). The mean duration of neutropenic period (+/-standard error) was 1.13+/-0.34 days in the DA-3030 group and 6.73+/-0.69 days in the control group respectively, and was significantly shorter in the DA-3030 group (p<0.0001). And, there was higher nadir ANC in the OA-3030 group than that in the control group (p=0.0001); the mean nadir ANC was 2,547+/- 343/mm and 442+/-120/mm, respectively. The DA-3030 group had significantly higher incidence of myalgia in comparison to the control group (43.8% compared with 3.3%; p=0.001). However, it was tolerable and was easily managed by conservative therapy CONCLUSION: The use of DA-3030 was effective in preventing chemotherapy-induced neutropenia.
Drug Therapy* ; Humans ; Incidence ; Myalgia ; Neutropenia* ; Neutrophils ; Random Allocation

Juvenile spring eruption(JSE) of the ears is an unusual type of photodermatosis, which develops on the light exposed areas of the ears of boys and young male adults in the early spring months. JSE has received little attention in the literature, and to our knowledge no cases have been reported in Korea until now. Herein we report a case of JSE occurring in a 17-year-old man who has suffered from a recurrent pruritic erythematous papulovesicular eruption of both helix, followed by crusting and healing without scarring within one to two months early each spring for six years.
Adolescent ; Adult ; Cicatrix ; Ear* ; Humans ; Korea ; Male

Reiters syndrome is an unusual disease characterized a triad of nongonococcal urethritis, conjunctivitis, and arthritis in association with the mircoutaneous lesions of keratoderma blenorrhagica and balarintis circinata. We present herein a case of Reiters syndome combined yiti lung cancer. A 39-year-old man has experienced naigrating polyarthralgia and high fever ilitermittently for about 20 years, Hyperkeratotic erythemnous patches and plaques, which dyeliped about 1 year ago, have aggravated and expanded to the whole body. Histopathologic sections from the plaque on the right forc ari showed characteristic findings including thickened parakeratotic horny layer and spongiform micropustules of Kogoji He was associated with HLA-B27. On the chest X-ray, a thumbtip size mass was incidently found. Chest CT and bone scan findings supported lung cancer and multiele metastases.
Adult ; Arthralgia ; Arthritis ; Conjunctivitis ; Fever ; HLA-B27 Antigen ; Humans ; Lung Neoplasms* ; Lung* ; Neoplasm Metastasis ; Thorax ; Tomography, X-Ray Computed ; Urethritis

The epidermal nevus syndrome is a disorder characterized by epidermal nevi and associated neurologic, skeletal, and other abnormalities. A 15-year-old female patient presented with extensive, bilateral systematized, verrucous plaques, involving the face, trunk, both extremities, and anogenital area. The onset of the lesions were at the age of 2 months. Abdominal CT showed the absence of the left kidney, teratoma of the right ovary and left ovarian cyst. This is a case of epidermal nevus syndrome, which was composed of extensive epidermal nevi, congenital solitary kidney, left ovarian cyst and right ovarian teratoma.
Adolescent ; Extremities ; Female ; Humans ; Kidney ; Nevus* ; Ovarian Cysts ; Ovary ; Teratoma ; Tomography, X-Ray Computed ; Urogenital Abnormalities*

The ultimate goal of blood donor screening for anti-hepatitis C virus(HCV) antibodies is the specific exclusion of vital carriers from the blood donor population. Recently, a third-generation anti-HCV screening (Lucky HCD 3.0) and immunoblot assay (Lucky Confirm) using antigens derived from the core and different nonstructural regioris (NS3, NS4 and NS5) of the HCV vital genome were developed. To evaluate the usefulness of these assays, anti-HCV reaction patterns of the RIBA-2 and the presence of HCV-RNA detected by reverse transcriptase-polymerase chain reaction(RT-PCR) were examined in 180 sera, which were repeatedly positive in Abbott EIA-2, and HCV seroconversion panel sera. The reaction intensity of HCD 3.0 was higher than that of HCD 2.0. The sensitivity and positive predictive value for vital carrier state of HCD 3.0 were 98.4% and 85.4%, respectively. HCD 3.0 assay enabled the detection of the antibody response 2 weeks earlier than did other second-generation EIAs. RT-PCR testing of sera with RIBA-2-indetermihate results showed that 33.3%(10/30) had evidence of HCV-RNA. However, all of nine Lucky Confirm-indeterminate cases were negative for HCV-RNA. The sensitivity and specificity of Lucky Confirm test were 99.2% and 76.4%, respectively, and the positive and negative predictive values were 90.5% and 97.7%, respectively.
Antibodies ; Antibody Formation ; Blood Donors ; Carrier State ; Genome ; Humans ; Immunoenzyme Techniques* ; Mass Screening ; Sensitivity and Specificity

No abstract available.
Child* ; Epidemiologic Studies* ; Gastroenteritis* ; Humans ; Rotavirus*

No abstract available.
Spinal Stenosis*

No abstract available.

PURPOSE: Soft tissue sarcomas are uncommon primary malignancies. So studies on the effective chemotherapy for soft tissue sarcomas are limited. We started this study to evaluate the effectiveness of VIP (etoposide, ifosfamide, cisplatin) combination chemotherapy for advanced soft tissue sarcomas. MATERIALS AND METHODS: Thirty patients with recurrent or metastatic soft tissue sarcoma were treated with VIP combination chemotherapy between December 1989 and June 1996. Each patient was given etoposide 75 mg/m2, ifosfamide 1000 mg/m2, cisplatin 20 mg/m2 intravenously for five consecutive days every three weeks. Mesna (sodium-2-mercaptoethansulfonate) was given to avoid the urologic toxicity. RESULTS: Twenty-eight of 30 patients were evaluable for response, and among the 28 evaluable patients, there were 9 partial response (32%). Duration of response in 9 responders ranged from 4.1 to 16.2 months (median 8.8 months). Overall survival ranged from 1.7 to 41.5 months (median 11 months) and survival was better for patients with partial response (median survival 14.8 months vs. 9.7 months with stable disease vs. 5.1 months with progressive disease p=0.0006). Nausea and vomiting was noted in more than 90% of cycles, but was markedly severe in only 4%. Leukopenia was noted in 60% of cycles, including 11% of cycles with counts <2,000/mm3. There was no treatment related death, but we had to stop chemotherapy in 2 patients due to leukopenia (1 patient) and neurotoxicity (1 patient). CONCLUSION: Combination of etoposide, ifosfamide, and cisplatin was fairly active for advanced soft tissue sarcoma, with myelosuppresion and peripheral neuropathy being the most serious toxicities.
Cisplatin* ; Drug Therapy* ; Drug Therapy, Combination ; Etoposide* ; Humans ; Ifosfamide* ; Leukopenia ; Mesna ; Nausea ; Peripheral Nervous System Diseases ; Sarcoma* ; Vomiting